Aligos Therapeutics Inc (NASDAQ: ALGS) has experienced a decline in its stock price by -19.25 compared to its previous closing price of 26.02. However, the company has seen a fall of -17.02% in its stock price over the last five trading days. globenewswire.com reported 2025-02-12 that Proceeds expected to fund the start of the ALG-000184 Phase 2 clinical study Funding expected to extend cash runway into the second half of 2026 SOUTH SAN FRANCISCO, Calif., Feb. 12, 2025 (GLOBE NEWSWIRE) — Aligos Therapeutics, Inc. (Nasdaq: ALGS, “Aligos”, “Company”), a clinical stage biotechnology company focused on improving patient outcomes through best-in-class therapies for liver and viral diseases, today announced that it has entered into a securities purchase agreement for a private placement that is expected to result in gross proceeds of approximately $105 million, before deducting placement agents’ fees and other expenses.
Is It Worth Investing in Aligos Therapeutics Inc (NASDAQ: ALGS) Right Now?
Company’s 36-month beta value is 2.45.Analysts have differing opinions on the stock, with 1 analysts rating it as a “buy,” 2 as “overweight,” 0 as “hold,” and 0 as “sell.”
The public float for ALGS is 2.64M, and currently, short sellers hold a 21.83% ratio of that floaft. The average trading volume of ALGS on February 13, 2025 was 434.57K shares.
ALGS’s Market Performance
ALGS’s stock has seen a -17.02% decrease for the week, with a -38.82% drop in the past month and a 106.18% gain in the past quarter. The volatility ratio for the week is 13.28%, and the volatility levels for the past 30 days are at 11.87% for Aligos Therapeutics Inc The simple moving average for the past 20 days is -24.19% for ALGS’s stock, with a 17.94% simple moving average for the past 200 days.
Analysts’ Opinion of ALGS
Many brokerage firms have already submitted their reports for ALGS stocks, with H.C. Wainwright repeating the rating for ALGS by listing it as a “Buy.” The predicted price for ALGS in the upcoming period, according to H.C. Wainwright is $75 based on the research report published on August 19, 2024 of the previous year 2024.
Piper Sandler, on the other hand, stated in their research note that they expect to see ALGS reach a price target of $3, previously predicting the price at $2. The rating they have provided for ALGS stocks is “Overweight” according to the report published on January 06th, 2023.
Jefferies gave a rating of “Buy” to ALGS, setting the target price at $3 in the report published on January 06th of the previous year.
ALGS Trading at -34.48% from the 50-Day Moving Average
After a stumble in the market that brought ALGS to its low price for the period of the last 52 weeks, the company was unable to rebound, for now settling with -55.11% of loss for the given period.
Volatility was left at 11.87%, however, over the last 30 days, the volatility rate increased by 13.28%, as shares sank -30.08% for the moving average over the last 20 days. Over the last 50 days, in opposition, the stock is trading -8.61% lower at present.
During the last 5 trading sessions, ALGS fell by -17.02%, which changed the moving average for the period of 200-days by +2.74% in comparison to the 20-day moving average, which settled at $27.71. In addition, Aligos Therapeutics Inc saw -47.26% in overturn over a single year, with a tendency to cut further losses.
Stock Fundamentals for ALGS
Current profitability levels for the company are sitting at:
- -15.77 for the present operating margin
- 0.66 for the gross margin
The net margin for Aligos Therapeutics Inc stands at -12.83. The total capital return value is set at -1.4. Equity return is now at value -146.69, with -88.31 for asset returns.
Based on Aligos Therapeutics Inc (ALGS), the company’s capital structure generated 0.15 points at debt to capital in total, while cash flow to debt ratio is standing at -9.31.
Currently, EBITDA for the company is -85.06 million with net debt to EBITDA at 0.28. When we switch over and look at the enterprise to sales, we see a ratio of 7.77. The liquidity ratio also appears to be rather interesting for investors as it stands at 3.81.
Conclusion
In a nutshell, Aligos Therapeutics Inc (ALGS) has experienced a mixed performance in recent times. The stock has received mixed “buy” and “hold” ratings from analysts. It’s important to note that the stock is currently trading at a significant distance from its 50-day moving average and its 52-week high.
